General MedicationsORALStandard
MYQORZO
AFICAMTEN
Standard Dose
5MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: N/A Marketing status: Prescription
Summary
Approval overview MYQORZO is listed in Drugs@FDA under application 219083 (NDA).
Review priority: N/A Marketing status: Prescription Active ingredient AFICAMTEN Form and strength TABLET;ORAL - 5MG Sponsor CYTOKINETICS Submission history Latest submission status date: 2026-02-05 00:00:00.
Structured Monograph
Clinical summary
Approval overview MYQORZO is listed in Drugs@FDA under application 219083 (NDA). Review priority: N/A Marketing status: Prescription Active ingredient AFICAMTEN Form and strength TABLET;ORAL - 5MG Sponsor CYTOKINETICS Submission history Latest submission status date: 2026-02-05 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: N/A
Interaction Notes
- No interaction notes stored yet.